Neurogene announces FDA Breakthrough Therapy designation for NGN-401 in Rett syndrome
Friday, February 27, 2026
Neurogene Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NGN-401, its investigational gene therapy for Rett syndrome.
The designation follows the FDA’s review of interim safety and efficacy data from an ongoing Phase 1/2 trial, based on a data cut-off of 30 October 2025. The review included patient-level results and supporting video evidence. The data showed clinically meaningful and durable functional improvements across several key areas of Rett syndrome, with patients continuing to gain skills over time.
NGN-401 is being developed as a one-time treatment. It delivers the full-length human MECP2 gene using the company’s EXACT™ transgene regulation technology. The therapy is administered via intracerebroventricular injection to enable broad delivery to the brain and nervous system, supported by nonclinical biodistribution findings.
The treatment is currently being studied in the Embolden™ registrational trial, with dosing expected to be completed in the second quarter of 2026.
Breakthrough Therapy designation is intended to speed up the development and review of medicines for serious conditions where early clinical evidence suggests clear improvement over existing options. The benefits include the possibility of Priority Review, rolling submission of a Biologics License Application, and closer guidance from the FDA on the most efficient route to approval.
In addition to this designation, NGN-401 has previously received Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations. It has also been selected for the FDA’s Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Programme.
Source: businesswire.com
